Generic LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE INN entry, drug patent and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TERRAMYCIN	lidocaine hydrochloride; oxytetracycline	INJECTABLE;INJECTION	060567-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pfizer	TERRAMYCIN	lidocaine hydrochloride; oxytetracycline	INJECTABLE;INJECTION	060567-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 8, 2026

Lidocaine hydrochloride is a mature, high-volume local anesthetic with durable demand across hospitals, dentistry, emergency medicine, outpatient procedures, and topical products. Its financial profile is driven by manufacturing reliability, sterile injectable capacity, supply contracts, and shortages rather than patent protection.

Oxytetracycline is an older tetracycline antibiotic with a smaller and more specialized commercial market. Its strongest remaining demand is in veterinary medicine, particularly long-acting injectable products for livestock. Human-market demand is limited in the United States, while veterinary products retain value through brand recognition, distribution, regulatory approvals, and manufacturing know-how.

Neither active ingredient has meaningful remaining compound-patent exclusivity in the United States. Competitive barriers are primarily regulatory, manufacturing, supply-chain, and channel-based.

What is the current market position of lidocaine hydrochloride?

Lidocaine hydrochloride is a mature generic active ingredient sold in several dosage forms:

Product category	Main uses	Commercial characteristics
Injectable lidocaine hydrochloride	Local anesthesia, regional anesthesia, cardiac arrhythmia management	High-volume institutional product; sterile manufacturing is the main barrier
Topical solution, gel, cream, and ointment	Dermal anesthesia, mucosal anesthesia, dental procedures	Fragmented retail, prescription, and medical-use market
Dental cartridges	Dental infiltration and nerve blocks	Stable procedural demand; packaging and device compatibility matter
Antiarrhythmic injection	Ventricular arrhythmias	Smaller volume, clinical importance, hospital procurement sensitivity
Combination products	Hemorrhoidal, dermatologic, oral, and pain products	Brand and formulation differentiation can support higher pricing

Demand is relatively inelastic in procedural settings. Hospitals require consistent supply even when unit prices are low. This creates a market in which a supplier can have modest revenue per unit but meaningful strategic value if competitors experience production interruptions.

The FDA lists lidocaine hydrochloride products across multiple approved dosage forms and strengths. The market includes products from Pfizer, Fresenius Kabi, Hikma, Sagent, Eugia, and other generic manufacturers, depending on presentation and supply status.[1]

How large is the lidocaine hydrochloride market?

No single public source provides a complete global revenue figure for lidocaine hydrochloride across prescription, hospital, dental, over-the-counter, compounded, and veterinary channels. Published commercial estimates vary because market researchers use different definitions of lidocaine, including or excluding combination products and non-hydrochloride formulations.

The economically relevant market can be divided into four segments:

Injectable hospital products.
Dental cartridges and office-based procedural products.
Topical prescription and consumer products.
Specialty formulations, including liposomal and transdermal delivery systems.

Injectable products usually have the strongest volume concentration but the lowest unit-price potential. Topical products have greater brand and formulation differentiation. Specialty delivery systems can generate higher revenue per treatment but do not materially expand the market for unmodified lidocaine hydrochloride.

What is driving lidocaine hydrochloride market growth?

Growth is gradual and volume-led rather than patent-led.

Hospital and ambulatory procedure demand

Lidocaine remains a standard component of local anesthesia for minor surgery, emergency treatment, catheter placement, dermatology, dentistry, and outpatient interventions. Growth in ambulatory procedures supports demand, but mature generic pricing limits revenue expansion.

Dental demand

Dental cartridges and topical anesthetics provide recurring demand with lower exposure to hospital purchasing tenders. Dental volumes are more resilient than many hospital products because lidocaine is embedded in routine procedures.

Drug shortages

Shortages can temporarily increase prices and market share for suppliers with available inventory. FDA shortage records have repeatedly identified local anesthetic products, including certain lidocaine presentations, as subject to supply disruption or constrained availability.[2] Shortage-driven revenue is generally temporary and can reverse when capacity returns.

Specialty formulations

Liposomal bupivacaine and other extended-release local anesthetics compete with conventional lidocaine in selected procedures. Their higher prices do not eliminate the broad use of low-cost lidocaine. They can reduce lidocaine utilization in selected postoperative or long-duration anesthesia applications.

What is the financial trajectory for lidocaine hydrochloride?

Lidocaine hydrochloride has a mature, low-growth financial profile.

Financial variable	Expected direction	Explanation
Unit volume	Stable to modestly rising	Supported by procedural and dental demand
Average selling price	Flat to declining in standard generics	Hospital tenders and multiple suppliers compress prices
Revenue	Stable, with periodic shortage spikes	Volume offsets price erosion in normal conditions
Gross margin	Highly variable	Depends on sterile capacity, labor, packaging, and procurement contracts
Capital intensity	Moderate to high for injectables	Sterile fill-finish, quality systems, and validation are required
Competitive risk	High	Multiple generic suppliers and limited product differentiation
Upside potential	Selective	Higher in prefilled syringes, cartridges, specialty packaging, or shortage-constrained presentations

For a generic manufacturer, profitability depends less on the molecule than on manufacturing position. A supplier with validated sterile lines, reliable API sourcing, and hospital distribution can earn attractive returns during constrained supply conditions. A supplier selling standard multi-dose vials into competitive tenders faces sustained price pressure.

Public companies generally report lidocaine within broader hospital products, injectables, anesthesia, or generic portfolios. They do not usually disclose lidocaine-specific revenue. As a result, company-level financial analysis must use product-channel indicators rather than isolated product sales.

What patents protect lidocaine hydrochloride?

The basic lidocaine molecule and conventional lidocaine hydrochloride formulations are long off patent.

Patent category	Current commercial significance
Compound patent	Expired
Basic lidocaine hydrochloride composition	Expired
Conventional injectable solution	Generally unprotected by meaningful current exclusivity
Topical cream, gel, or spray	Product-specific formulation patents may exist, but the active ingredient is unprotected
Liposomal or extended-release delivery	May have active formulation or platform patents, depending on product
Device or packaging	May carry separate patents or regulatory protections

The principal patent risk does not involve generic entry against the lidocaine molecule. It involves formulation-specific products, delivery systems, devices, or combination products. A conventional lidocaine hydrochloride injection is unlikely to support a durable patent moat.

What is the FDA and Orange Book status of lidocaine hydrochloride?

Lidocaine hydrochloride is FDA-approved in multiple dosage forms. Approved human drug products may be listed in the FDA’s Orange Book when they meet the applicable listing criteria.[1]

The relevant regulatory structure is:

Conventional generic injections are generally approved through abbreviated new drug applications.
Topical products may use ANDA, 505(b)(2), or other product-specific pathways.
Combination products can involve additional formulation and labeling requirements.
Injectable products must meet sterility, particulate, container-closure, and manufacturing controls.
No biosimilar pathway applies because lidocaine hydrochloride is a small-molecule drug.

There is no practical NCE exclusivity remaining for the underlying active ingredient. Any remaining exclusivity would be tied to a specific newer formulation or product, not to standard lidocaine hydrochloride.

What is the competitive landscape for lidocaine hydrochloride?

Competition is strongest in standard injectable presentations. Key competitive variables include:

Number of approved suppliers.
FDA shortage status.
Sterile manufacturing capacity.
Hospital group-purchasing contracts.
Availability of preservative-free and epinephrine-containing presentations.
Vial, syringe, cartridge, and ampule formats.
Quality history and supply reliability.

Hospira, now part of Pfizer, Fresenius Kabi, Hikma, Sagent, and other generic suppliers have participated in the U.S. injectable market. The supplier list varies by strength, presentation, and current commercial availability.

What is the current market position of oxytetracycline?

Oxytetracycline is a first-generation tetracycline antibiotic. Its commercial center of gravity has shifted from human medicine to veterinary medicine.

The principal products are:

Product category	Main uses	Commercial characteristics
Long-acting injectable veterinary products	Bacterial infections in cattle, swine, sheep, and other livestock	High value per treatment; brand and field-use reputation matter
Conventional veterinary injection	Broad livestock indications	Mature product with competition from generic and branded suppliers
Ophthalmic veterinary ointment	Eye infections in companion animals and livestock	Smaller market; formulation and distribution are important
Human oral or parenteral products	Historically broad antibacterial use	Limited current U.S. commercial relevance
Agricultural and international products	Animal-health applications outside the U.S.	Regulatory and country-specific demand vary

Zoetis’ LA-200 is a recognized oxytetracycline veterinary product in the United States. Generic and regional competitors also sell oxytetracycline products, particularly outside the U.S.[3]

How large is the oxytetracycline market?

The oxytetracycline market is materially smaller than the overall tetracycline or animal-antibiotic market. Public market estimates are inconsistent because they may include doxycycline, tetracycline, chlortetracycline, combination products, or all veterinary antibiotics.

The commercially relevant market is concentrated in:

Livestock injectable antibiotics.
Long-acting treatment products.
Veterinary ophthalmic products.
Emerging markets where older injectable antibiotics remain widely used.
Animal-health distributors serving cattle, swine, sheep, and companion-animal channels.

In the United States, veterinary revenue is more important than human pharmaceutical revenue. In international markets, human and veterinary demand may coexist, but pricing and regulatory controls differ substantially by country.

What is driving oxytetracycline market growth?

Oxytetracycline is a mature product with limited structural growth.

Livestock disease management

Demand follows livestock populations, disease incidence, veterinary prescribing, and farm economics. Cattle and swine production cycles affect volume. Injectable products remain useful where rapid treatment and field administration are prioritized.

Long-acting formulations

Long-acting products reduce dosing frequency and can command a premium over conventional formulations. The value proposition depends on dosing convenience, withdrawal periods, tissue residues, and animal-health outcomes.

Emerging-market access

Older broad-spectrum antibiotics retain demand in countries where advanced veterinary products are less accessible or more expensive. This supports unit volume but can produce lower prices and greater regulatory variability.

Antimicrobial stewardship

Regulatory controls on medically important antibiotics create a structural constraint. In the United States, FDA policies have limited medically important antimicrobial use for growth promotion and require veterinary oversight for certain uses.[4] These measures can reduce discretionary volume while preserving treatment demand.

What is the financial trajectory for oxytetracycline?

Oxytetracycline has a stable-to-declining mature-market trajectory in developed markets and more resilient volume in selected international veterinary markets.

Financial variable	Expected direction	Explanation
U.S. human revenue	Low and limited	Few commercially important human products
U.S. veterinary revenue	Stable to modestly declining	Established livestock demand but stewardship pressure
International volume	Stable or rising in selected regions	Access and livestock growth support demand
Pricing	Mixed	Brand premiums coexist with generic price pressure
Gross margin	Higher for differentiated long-acting brands	Formulation, distribution, and regulatory status support pricing
Patent contribution	Minimal for the active ingredient	Commercial value comes from product execution
Regulatory risk	Rising	Stewardship and residue requirements constrain use
Revenue volatility	Moderate	Exposed to livestock cycles, supply, and government policy

Zoetis reports animal-health revenue at a portfolio level and does not generally disclose LA-200 or oxytetracycline-specific sales. Oxytetracycline products are therefore better analyzed as contributors to an animal-health franchise than as standalone financial assets.[5]

What patents protect oxytetracycline?

The oxytetracycline compound is long off patent. Conventional oxytetracycline injectable products do not have meaningful active compound exclusivity.

Potentially relevant rights may involve:

Long-acting suspension formulations.
Stabilizers and excipient systems.
Concentration and dosing regimens.
Veterinary use claims.
Container or delivery systems.
Manufacturing processes.
Combination products.

These rights are product-specific. They do not prevent competition from conventional oxytetracycline products once the relevant patent term expires or where the competing product does not practice the claimed invention.

What is the FDA regulatory status of oxytetracycline?

Veterinary oxytetracycline products are regulated as animal drugs and may be approved through abbreviated new animal drug applications. The FDA Green Book identifies approved animal drug products and related application information.[6]

Important regulatory variables include:

Species-specific labeling.
Indications and dosage.
Withdrawal periods for meat, milk, and eggs.
Residue limits.
Prescription or veterinary-feed-directive status.
Manufacturing controls.
Environmental and antimicrobial-stewardship requirements.

The FDA’s animal-drug framework creates a higher barrier than the molecule’s age might suggest. A competitor must establish bioequivalence or other applicable approval standards and comply with species, residue, and manufacturing requirements.

Which companies compete in oxytetracycline?

Competition includes branded animal-health companies, generic veterinary manufacturers, and regional distributors. Zoetis is the most visible U.S. branded participant through LA-200. Other competitors vary by country and product presentation.

Competitive differentiation depends on:

Brand trust among veterinarians and producers.
Distributor access.
Long-acting performance.
Dosing convenience.
Withdrawal periods.
Supply reliability.
Price per treated animal.
Regulatory approvals in target species.

Generic entry is more feasible for conventional formulations than for differentiated long-acting products. The latter may retain commercial protection through manufacturing complexity, data packages, brand loyalty, and channel control even without active patent protection.

How do the patent estates and commercial outlooks compare?

Factor	Lidocaine hydrochloride	Oxytetracycline
Core patent status	Expired	Expired
Main market	Human hospital, dental, topical	Veterinary livestock and selected ophthalmic uses
Demand profile	Broad and recurring	Narrower and livestock-dependent
Growth	Low, volume-led	Flat to modest decline in developed markets
Main barrier	Sterile manufacturing and supply reliability	Veterinary approvals, formulations, distribution
Generic pressure	High	High for conventional products
Brand value	Moderate in specialty formats	More meaningful in branded veterinary products
Shortage upside	Significant for injectables	Possible but less systemically visible
Biosimilar risk	None	None
Patent litigation risk	Low for conventional products	Low for conventional products
Financial visibility	Embedded in hospital portfolios	Embedded in animal-health portfolios

Lidocaine has the stronger base market because it is used across multiple medical specialties. Oxytetracycline has more defensible brand economics in certain veterinary formulations, but its total addressable market is smaller and subject to greater regulatory pressure.

What generic launch scenarios exist?

Lidocaine hydrochloride

A new entrant would face intense price competition in standard vials and ampules. The most attractive opportunities are:

Shortage-constrained presentations.
Preservative-free products.
Prefilled syringes.
Dental cartridges.
Reliable supply to group-purchasing organizations.
Topical or combination products with differentiated packaging.

The base-case launch outcome is gradual share capture with low pricing power. A shortage or competitor exit can produce rapid but temporary revenue expansion.

Oxytetracycline

A generic entrant would have better prospects in markets where:

Veterinary distribution is fragmented.
The reference product has limited supply.
Long-acting presentations command a price premium.
Local manufacturing reduces import exposure.
Livestock production is expanding.

The base case is a lower-price conventional product competing on availability and distribution. A differentiated long-acting product has greater revenue potential but requires more regulatory and manufacturing investment.

What litigation and Paragraph IV risks exist?

No major current Paragraph IV litigation is central to the commercial outlook for conventional lidocaine hydrochloride or oxytetracycline. Their core patents expired long ago, and standard products are generally subject to ordinary generic competition.

Potential disputes can still arise over:

Formulation patents.
Delivery systems.
Device components.
Labeling and method-of-use claims.
Trade dress and trademark rights.
Manufacturing processes.
Regulatory exclusivity for newer products.

For lidocaine, litigation risk is more relevant to advanced delivery systems and branded combinations. For oxytetracycline, it is more relevant to long-acting veterinary formulations and branded product differentiation.

What licensing deals affect these markets?

Licensing is not a major value driver for the unmodified active ingredients. Transactions are more likely to involve:

Contract manufacturing.
Regional distribution.
Veterinary product rights.
Device or packaging technology.
Specialty topical formulations.
Acquisition of animal-health portfolios.

Large pharmaceutical companies generally do not disclose product-level licensing economics for mature generic lidocaine or oxytetracycline products. Commercial control is more often obtained through manufacturing agreements, distribution contracts, or portfolio acquisitions than through molecule-level licenses.

Key Takeaways

Lidocaine hydrochloride is a resilient, mature generic with broad human-health demand.
Its financial performance depends on sterile manufacturing, hospital contracts, dental distribution, and shortage conditions.
Oxytetracycline is primarily a veterinary commercial asset, especially in long-acting livestock injectables.
Both active ingredients are long off patent.
Conventional generic entry is legally feasible, but regulatory and manufacturing execution remain important.
Lidocaine has the larger and more diversified market.
Oxytetracycline has greater dependence on veterinary branding, livestock economics, stewardship policy, and distribution.
Neither product has biosimilar risk because both are small-molecule drugs.
Product-specific formulation, device, process, and method-of-use rights may still matter even though compound patents have expired.

FAQs

Is lidocaine hydrochloride still profitable for pharmaceutical manufacturers?

Yes, but profitability is uneven. Standard injectable products face price compression, while suppliers with reliable sterile capacity can benefit from shortages, institutional contracts, and specialized presentations.

Is oxytetracycline still used in human medicine?

Its human use is limited in the United States compared with newer tetracyclines such as doxycycline. Current commercial significance is concentrated in veterinary products and selected international markets.

Does lidocaine hydrochloride have active Orange Book patents?

The basic active ingredient and conventional formulations are not protected by meaningful current compound patents. Any active rights would generally relate to specific formulations, devices, combinations, or delivery technologies.

Is LA-200 protected by a patent?

The oxytetracycline active ingredient is not patent-protected as a new compound. Commercial protection for LA-200 depends more on product approvals, formulation know-how, trademarks, manufacturing, distribution, and customer loyalty than on basic molecule exclusivity.

Which drug has stronger long-term market prospects, lidocaine hydrochloride or oxytetracycline?

Lidocaine hydrochloride has stronger long-term prospects because it serves larger and more diversified procedural markets. Oxytetracycline remains commercially viable but has narrower demand and greater exposure to antimicrobial stewardship and livestock-market conditions.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
U.S. Food and Drug Administration. (2024). Drug shortages database. FDA.
Zoetis Inc. (2024). LA-200 oxytetracycline injection product information. Zoetis.
U.S. Food and Drug Administration. (2017). The judicious use of medically important antimicrobial drugs in food-producing animals. FDA.
Zoetis Inc. (2024). 2023 annual report. Zoetis.
U.S. Food and Drug Administration. (2024). Green Book: Approved animal drug products. FDA.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	5,387
DailyMed Link:	lidocaine hydrochloride; oxytetracycline at DailyMed

Summary for lidocaine hydrochloride; oxytetracycline

Anatomical Therapeutic Chemical (ATC) Classes for lidocaine hydrochloride; oxytetracycline